{"commentary":{"count":4,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT02193282","nct_id":"NCT02193282","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02193282. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Blinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)","label":"Arm A (blinded erlotinib hydrochloride)","type":"EXPERIMENTAL"},{"description":"Patients receive placebo PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. (CLOSED 06/14/17)","label":"Arm B (placebo)","type":"PLACEBO_COMPARATOR"},{"description":"Unblinded patients receive erlotinib hydrochloride PO QD on days 1-21. Treatment repeats every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","label":"Arm C (unblinded erlotinib hydrochloride)","type":"EXPERIMENTAL"},{"description":"Patients (including patients previously randomized to placebo) undergo observation at least every 6 months for 2 years.","label":"Arm D (observation)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-02-03","type":"ESTIMATED"},"conditions":["Lung Non-Squamous Non-Small Cell Carcinoma","Stage IB Lung Non-Small Cell Carcinoma AJCC v7","Stage II Lung Non-Small Cell Cancer AJCC v7","Stage IIA Lung Non-Small Cell Carcinoma AJCC v7","Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","Stage IIIA Lung Non-Small Cell Cancer AJCC v7"],"enrollment":{"count":390,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Clinical Observation","type":"OTHER"},{"name":"Erlotinib Hydrochloride","type":"DRUG"},{"name":"Laboratory Biomarker Analysis","type":"OTHER"},{"name":"Placebo Administration","type":"OTHER"}],"last_update":"2026-07-02","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-12-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"The time from randomization until death, assessed up to 10 years"}],"references":[],"start_date":{"date":"2015-02-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","url":"https://clinicaltrials.gov/study/NCT02193282"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02193282"}